- Home
- FNWB vs BCAB Comparison
FNWB vs BCAB Comparison
Compare FNWB & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWB | BCAB |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 71.6M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FNWB | BCAB |
|---|---|---|
| Price | $9.35 | $0.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $1.00 |
| AVG Volume (30 Days) | 35.2K | ★ 1.5M |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,052,000.00 | N/A |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $0.24 |
| 52 Week High | $12.10 | $1.43 |
Technical Indicators
Market Signals| Indicator | FNWB | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 38.92 |
| Support Level | $9.30 | $0.55 |
| Resistance Level | $10.08 | $0.82 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 3.82 | 12.73 |
Price Performance
Historical ComparisonAbout FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.